What is the current price and volume for GV.PA stock pre-market?

Pre-market on 27 Jan 2026 GV.PA stock trades near **€0.002** with volume at **38.49M** shares, about **2.71x** its average, making it one of the most active names on EURONEXT.

What drivers should traders watch for GV.PA analysis?

Traders should watch partnership news, FiberVision commercial updates, clinical validation milestones and any financing announcements, as these materially affect GV.PA stock liquidity and short-term price moves.

How does Meyka AI rate GV.PA and what does the forecast show?

Meyka AI rates GV.PA with a score out of 100: **58.64 (C+)** with suggestion HOLD. The model projects a 12-month base-case **€0.0025**, implying about **+38.89%**, with downside risks noted.

Is GV.PA a buy for long-term investors?

GV.PA Genomic Vision SA stock shows high risk: negative earnings, tight liquidity and a small market cap. Long-term investors should require clear commercial progress or financing before adding exposure.

EU Stocks

GV.PA Genomic Vision EURONEXT €0.002 pre-market: heavy volume, watch upside

ByHuzaifa Zahoor January 27, 2026

On 27 Jan 2026 pre-market we see GV.PA stock trading at €0.002 on EURONEXT after a strong intraday volume spike of 38.49M shares, about 2.71x its 50-day average. That surge makes Genomic Vision (GV.PA) one of the most active small-caps in the Healthcare sector this session and sets the stage for volatile price action as traders reassess liquidity, valuation and news flow.